Biomarkers for Renal Cell Carcinoma Recurrence: State of the Art

Purpose of Review We aim to summarize the current state of art about the possible use of biomarkers for predicting renal cell carcinoma (RCC) recurrence after curative treatment. In addition, we aim to provide a snapshot about the clinical implication of biomarkers use for follow-up planification. Recent Findings A wide variety of biomarkers have been proposed. RCC biomarkers have been individuated in tumoral tissue, blood, and urine. A variety of molecules, including proteins, DNA, and RNA, warrant a good accuracy for RCC recurrence and progression prediction. Their use in prediction models might warrant a better patients' risk stratification. Future prognostic models will probably include a combination of classical features (tumor grade, stage, etc.) and novel biomarkers. Such models might allow a more accurate treatment and follow-up planification.

Automated summary

This review summarizes the current state of using biomarkers to predict RCC recurrence after curative treatment, highlighting the accuracy and clinical implications of various biomarkers in prediction models. Future prognostic models may combine classical features with novel biomarkers for more accurate treatment and follow-up planning.